Testing different immune-suppressing treatments for membranous kidney disease
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 3 trial compares different immune-suppressing medicines for idiopathic membranous nephropathy (a kidney disease caused by the immune system). It may help reduce heavy protein leakage in the urine and improve disease control in people who fit specific prior-treatment and lab requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have idiopathic membranous nephropathy (your doctors say it’s not caused by another condition).
- You are post-menopausal, or you can use effective birth control and are not planning pregnancy.
- You’ve been off steroids and mycophenolate for over 1 month, and off alkylating drugs or rituximab for over 6 months.
- You’ve used an ACE inhibitor or ARB for at least 3 months with blood pressure that was controlled (unless you can’t tolerate it).
- Your urine protein is at least 4 grams per day, and it has not dropped more than 50% from your usual baseline.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications, rituximab and cyclosporine, for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The goal is to see if this combination can reduce protein loss and improve kidney function, potentially preserving kidney health.
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
This study tests a new medicine called JMT601 for people with primary membranous nephropathy (a kidney condition causing protein leakage). The goal is to see if the medicine can reduce protein in the urine while being safe.
This trial looks at how people with primary membranous nephropathy (a kidney disease that causes swelling and protein in urine) do over time with their current treatment. It helps doctors understand which treatments work best, especially for those with severe protein loss.
This trial is testing a new kind of immune therapy, called UCAR-T, which uses reprogrammed white blood cells to help treat a severe type of kidney disease (membranous nephropathy) that has not improved with standard medicines. The goal is to see if this therapy can calm the immune attack on the kidneys and reduce protein loss in urine.
Hear when a new Idiopathic Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.